3-[2-[[(2R,3S,4R)-3-[4-(4-cyclohexylbutylcarbamoyl)-1,3-oxazol-2-yl]-7-oxabicyclo[2.2.1]heptan-2-yl]methyl]-4-fluorophenyl]propanoic acid

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 英文名称: 3-[2-[[(2R,3S,4R)-3-[4-(4-cyclohexylbutylcarbamoyl)-1,3-oxazol-2-yl]-7-oxabicyclo[2.2.1]heptan-2-yl]methyl]-4-fluorophenyl]propanoic acid
• 化学式: C₃₀H₃₉FN₂O₅
• 分子量: 526.6
• InChiKey: RTQPDALMIQZXTN-GDLOATEISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.3
• 重原子数：
  38
• 可旋转键数：
  12
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.63
• 拓扑面积：
  102
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• PROSTAGLANDIN E RECEPTOR ANTAGONISTS
  申请人：Woodward David F.

  公开号：US20100256385A1

  公开（公告）日：2010-10-07

  The present invention provides prostaglandin receptor antagonist compounds represented by the general formula I, wherein A, R, R 1 and R 2 are as defined in the specification.

  本发明提供了由一般式I表示的前列腺素受体拮抗剂化合物，其中A、R、R1和R2如规范中所定义。
• Prostaglandin D2 antagonist
  申请人：Allergan, Inc.

  公开号：US20040162323A1

  公开（公告）日：2004-08-19

  Disclosed herein is compound 1 1 or a pharmaceutically acceptable salt, or a prodrug thereof. Compound 1 is useful for treating or preventing a variety of diseases or conditions. Results presented herein also demonstrate that Compound 1 is a prostaglandin D 2 antagonist, and as such is useful in the treatment or prevention of prostaglandin D 2 mediated conditions or diseases. A method comprising administering a prostaglandin D 2 antagonist to a mammal suffering from a disease or condition selected from the group consisting of the gastrointestinal tract disorders or diseases, hyperalgesia, allodynia, abdominal cramping, glaucoma, ocular hypertension, and ocular hypotension is also disclosed herein. Pharmaceutical compositions and products comprising compound 1 are also disclosed.

  本文披露了化合物11或其药学上可接受的盐或前药。化合物1可用于治疗或预防多种疾病或症状。本文还表明，化合物1是一种前列腺素D2拮抗剂，因此可用于治疗或预防前列腺素D2介导的疾病或症状。本文还披露了一种方法，包括向患有来自选组中的胃肠道紊乱或疾病、高痛觉、触觉过敏、腹部痉挛、青光眼、眼压高或眼压低的哺乳动物施用前列腺素D2拮抗剂。本文还披露了包含化合物1的制药组合物和产品。
• Interheteroaryl 7-oxabicyclic [2.2.1]heptane oxazoles as prostaglandin F2alpha antagonists
  申请人：——

  公开号：US20020128233A1

  公开（公告）日：2002-09-12

  The present invention provides novel compounds represented by the general 1 wherein m, n, X, Y, Z, R, R 1 and R 2 are as defined in the specification or a pharmaceutically acceptable salt thereof. The novel compounds are PGF 2&agr; antagonists, useful in pharmaceutical compositions for treating PGF 2&agr; -mediated disease responses such as inflammatory reactions relating to rheumatoid arthritis and psoriasis, reproductive disorders, bronchoconstrictive disorders (asthma), excessive bone breakdown (osteoporosis), peptic ulcers, heart disease, platelet aggregation and thrombosis.

  本发明提供了由通式1表示的新化合物，其中m，n，X，Y，Z，R，R1和R2如规范中定义或其药学上可接受的盐。这些新化合物是PGF2α拮抗剂，可用于制备药物组合物，用于治疗PGF2α介导的疾病反应，如与类风湿性关节炎和牛皮癣有关的炎症反应，生殖障碍，支气管收缩性疾病（哮喘），过度骨质破坏（骨质疏松症），消化性溃疡，心脏病，血小板聚集和血栓形成。
• US6511999B2
  申请人：——

  公开号：US6511999B2

  公开（公告）日：2003-01-28
• US7217725B2
  申请人：——

  公开号：US7217725B2

  公开（公告）日：2007-05-15